OABI logo

OmniAb, Inc.

OABI
Healthcare|Biotechnology|US
$5.03
+0.20 (+4.14%)
Tangible Book / Share
$0.40
Cash / Share
$0.50

About

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.

Stock Price

+264.5%(1Y)
1M
+7.9%
3M
+63.3%
6M
+203.0%
YTD
+171.9%
1Y
+237.6%
3Y
+10.5%
5Y
-49.5%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$733.7M
Employees89 (-22% YoY)
CEOMatthew W. Foehr
IPO DateSep 30, 2021
Beta1.05
52-Week Range$1.35 – $5.43
Avg Volume1,403,328
ExchangeNASDAQ
Websiteomniab.com

Ownership

Float81.4%
Shares Outstanding145.9M

Recent Insider Trades

Love StevenOPTION EX.
Nov 1, 202613,334 shares
Love StevenOPTION EX.
Nov 1, 202613,334 shares
Nwachuku Amechi EkekeAWARD
Aug 1, 2026800,000 shares @ $1.98
Nwachuku Amechi EkekeOTHER
Jul 13, 20260 shares
Bertozzi Carolyn ROPTION EX.
Jun 17, 202620,000 shares

Peers

ABSIAbsci Corporation
$1.75B
MGNXMacroGenics, Inc.
$148.4M
STROSutro Biopharma, Inc.
$159.5M
VRXAVeraxa Biotech Holding AG
$134.3M
Data last updated: Nov 9, 2026, 04:25 AM